Literature DB >> 27235856

C(16)-C(22) oxygen-bridged analogues of ceDAF-12 and LXR ligands.

M Celeste Del Fueyo1, M Virginia Dansey1, Luciano S Paolo2, Adalí Pecci2, Adriana S Veleiro1, Gerardo Burton3.   

Abstract

The DAF-12 receptor in nematodes and the Liver X Receptor (LXR) in mammals are structurally related transcription factors that play key roles in determining the life span of the organism. Both types of receptors are activated by oxysterols, cholesterol metabolites with oxidized side chains. Restricting the movement of the oxysterol side chain to certain orientations may have profound effects in the activity profile, however this has not been explored so far. In a first attempt to obtain analogues of natural ligands of DAF-12 and LXR with restricted side chain mobility we introduced a 16,22-oxygen bridge in 26-hydroxycholesterol, a cholestenoic acid and a dafachronic acid (5-7). Diosgenin was used as starting material, the key step to obtain the 16,22 epoxy functionality was the one pot formation and reduction of a cyclic hemiketal via the oxocarbenium ion using sodium cyanoborohydride. All new compounds were characterized by NMR and mass spectrometry and assayed as ceDAF-12 or LXR ligands in transactivation cell-based assays. The dafachronic acid analogue 7 behaved as a ceDAF-12 agonist.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DAF-12 receptor; Dafachronic acid; Liver X Receptor; Oxocarbenium reduction; Oxysterols

Mesh:

Substances:

Year:  2016        PMID: 27235856     DOI: 10.1016/j.steroids.2016.05.009

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  2 in total

1.  Synthesis and Antitumor Activity of Diosgenin Hydroxamic Acid and Quaternary Phosphonium Salt Derivatives.

Authors:  Lin Wang; Maoling Yao; Yuegao Hu; Congdi Chen; Liming Jin; Xiaodong Ma; Hongjun Yang
Journal:  ACS Med Chem Lett       Date:  2022-04-19       Impact factor: 4.632

2.  Dihydrodiosgenin protects against experimental acute pancreatitis and associated lung injury through mitochondrial protection and PI3Kγ/Akt inhibition.

Authors:  Yan Shen; Li Wen; Rui Zhang; Zeliang Wei; Na Shi; Qiuyang Xiong; Qing Xia; Zhihua Xing; Zhi Zeng; Hai Niu; Wen Huang
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.